Dr Andrews
IntelliCell BioSciences Joins Forces With Dr. James Andrews's Research and Educational Foundation
Press Release: IntelliCell BioSciences, Inc. – 9 minutes ago
Email:
Recommend:
Tweet:
RELATED CONTENT
RELATED QUOTES
| Symbol | Price | Change |
|---|---|---|
| SVFC | 0.009 | +0.002 |
NEW YORK, NY—(Marketwired - Mar tz, 2014) - IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed a license agreement with Dr. James Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida for the installation of its cGTP Cellular Processing Lab for the manufacturing of Stromal Vascular Fraction Cells (SVFC).
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a huge step for IntelliCell BioScienses in the fields of orthopedic and sports medicine. IntelliCell's SVF cellular product has helped many professional and non-professional athletes with their injuries, allowing them to return to their careers and everyday life. With Dr. Andrews on board we will be able to advance the research and science of the SVF cellular product in the fields of orthopedic and sports medicine. We at IntelliCell believe Dr. Andrews's world-class experience and knowledge is unparalleled in the arena of treating injured athletes, and with Dr. Andrews' guidance IntelliCell should be able to make significant inroads."
As the new Chairman of the IntelliCell Orthopedic Cellular Therapy Advisory Board, Dr. James Andrews stated, "We at the Andrews's Research and Educational Foundation have recently joined forces with Intelicell BioSciences to participate in their autologous stem cell research. We are excited at the opportunity of developing a first class biological laboratory at our facility in conjunction with Intelicell BioSciences that will allow us to continue our effort towards excellence in clinical stem cell therapy research."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
About Dr. James Andrews
Dr. James Andrews is internationally known and recognized for his scientific and clinical research contributions in knee, shoulder and elbow injuries, as well as his skill as an orthopedic surgeon. Dr. Andrews is a founding partner and medical director for the Andrews Institute in Gulf Breeze, Florida. In addition, he is a founding member ofthe American Sports Medicine Institute (ASMI). Dr. Andrews has been the mentor for more than 250 orthopedic/sports medicine fellows and more than 45 primary care sports medicine fellows. Involved in education and research in sports medicine and orthopedic surgery, he has made major presentations on every continent, and has authored numerous scientific articles and books.
Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Contact:
IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
Email Contact
Steven Victor MD
IntelliCell BioSciences
Chairman/CEO
460 Park Avenue 17th Floor
New York, New York 10022
212-249-3050
Fa
CANE=
www.IntelliCellBioSciences.com